AI in Clinical Trials Market Projected to Reach USD 7.32 Billion by 2034

The global market for Artificial Intelligence (AI) in clinical trials is expected to reach USD 7.32 billion by 2034, growing from an estimated USD 2 billion in 2025. According to analysis by Maximize Market Research, the market is projected to expand at a compound annual growth rate (CAGR) of 15.5% from 2026 to 2034.

AI is reshaping the landscape of clinical research by enhancing patient recruitment, improving data analysis, and accelerating drug development processes. Pharmaceutical, biotechnology companies, and Contract Research Organizations (CROs) are increasingly adopting AI tools for patient screening, cohort selection, trial design, and safety monitoring.

Key technologies driving this growth include machine learning, natural language processing, and deep learning. These advancements enable researchers to identify suitable trial participants more efficiently and to detect patterns within complex patient datasets, leading to more targeted clinical decision-making and reduced development timelines.

North America currently leads the market, supported by its strong healthcare infrastructure and significant investment in AI research and development. Europe is also witnessing rapid adoption. Emerging trends such as decentralized trials and AI-driven patient monitoring are further contributing to the market's expansion.